Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03616483 · ClinicalTrials.gov registry record

The Indiana Myeloma Registry

A clinical trial of Plasma Cell Dyscrasias, sponsored by Indiana University.

Recruiting
Registry status
2,500
Enrollment target
1
Study location

NCT03616483: Recruiting study of Plasma Cell Dyscrasias, sponsored by Indiana University.

NCT03616483 is a study of Plasma Cell Dyscrasias that is actively recruiting participants, run by Indiana University. The registered enrollment target is 2,500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03616483, a study of Plasma Cell Dyscrasias, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
2,500 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research

Primary Outcome

The primary objective of this study is to provide a mechanism to store comprehensive clinical, genomic, demographic, social, environmental and quality of life data from subjects with plasma cell dyscrasias

Conditions Studied

Interventions

  • OTHER This is a non-interventional trial

Study Locations (1)

Indiana

  • Indiana University Simon Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 2,500 participants
Start Date 2018-06-18
Est. Completion 2028-06-30
Indiana University

890 total trials

What NCT03616483 shows while recruiting

NCT03616483 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.

The record links to 1 condition, with Plasma Cell Dyscrasias appearing as the primary indexed condition, and to 1 intervention - of which This is a non-interventional trial is the first listed.

NCT03616483 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT03616483 about?

NCT03616483 is a clinical study titled "The Indiana Myeloma Registry". This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research

What is the current status of trial NCT03616483?

This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2018-06-18. Estimated completion is 2028-06-30.

What conditions does trial NCT03616483 study?

This clinical trial studies the following conditions: Plasma Cell Dyscrasias.

What interventions are being tested in trial NCT03616483?

The interventions under investigation include: This is a non-interventional trial (OTHER).

Who is sponsoring clinical trial NCT03616483?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03616483 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Plasma Cell Dyscrasias

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001160 · 2,500 participants

    Studies on Tumors of the Thyroid

  • NCT01904188 · 2,500 participants

    Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

  • NCT02257229 · 2,500 participants

    Prospective Evaluation of Treatment for Clubfoot

  • NCT02530658 · 2,500 participants

    Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03616483, the US trial registry maintained by the National Library of Medicine. NCT03616483 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.